News
CEO Martin Olin steps down
BerGenBio ASA: Minutes from Extraordinary General Meeting
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer
BerGenBio ASA: Registration of share capital reduction
BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast